INTS
INTENSITY THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.29
−1.79%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.27
From 52W high−90.03%
Volume7141.00
Market cap$10.74M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$3.27
From 52W high
−90.03%
Volume
7141.00
Market cap
$10.74M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
P/E (TTM)
—
RSI (14)
36.9
MomentumView details →
1D Return
−1.79%
YTD Return
−68.62%
SummaryUpdated Jun 1, 2026
Intensity Therapeutics, Inc. (NASDAQ:INTS) is a clinical-stage biotechnology company founded in 2012 and headquartered in Westport, Connecticut. The company went public in June 2023 and focuses on developing innovative cancer treatments for solid tumors. Intensity Therapeutics operates in the oncology drug development space, with its lead product candidate currently in Phase 2 clinical trials for treating various refractory solid tumors including pancreatic, colon, bile duct, and other challenging cancers.
Similar companies
Latest newsMore news →